Merck(US:MRK) 智通财经网·2025-11-18 15:37Core Viewpoint - Merck (MRK.US) shares rose over 4% to $96.97 following FDA approval of its pulmonary hypertension therapy, Winrevair, which achieved primary endpoints in patients with pulmonary hypertension [1] Group 1: Drug Approval and Efficacy - The FDA approved Winrevair for treating pulmonary hypertension, a condition characterized by elevated blood pressure in the pulmonary blood vessels [1] - Data from the 24-week Phase 2 CADENCE study indicated that Winrevair significantly reduced pulmonary vascular resistance, meeting the trial's primary endpoint with both statistical and clinical significance [1] - The study aimed to evaluate the efficacy of the injection compared to a placebo in adult patients with pre-capillary and post-capillary pulmonary hypertension due to heart failure with preserved ejection fraction (HFpEF) [1] Group 2: Safety and Future Plans - The company reported that Winrevair's tolerability aligns with established safety profiles [1] - Merck plans to present the study results at future medical conferences and continue advancing the drug's late-stage projects in CpcPH caused by HFpEF [1]